Innovative Radioligand Therapy for HER2-Positive Cancers Begins First Human Trials

The McGill University Health Centre (MUHC) has embarked on a pioneering phase 1 clinical trial testing a novel radioligand therapy aimed at HER2-positive cancers. Sponsored by Novartis, this trial is the first of its kind globally to assess the safety and efficacy of this innovative treatment in patients with cancer that has progressed despite existing therapies.

HER2-positive cancers are characterized by the overexpression of the HER2 protein on the surface of cancer cells and can include breast, lung, stomach, and bladder cancers. These cancers tend to be more aggressive, and while HER2-targeted therapies have improved outcomes, resistance and disease progression remain challenges. This trial seeks to explore new avenues for patients with metastatic cancer who have exhausted all other targeted treatments.

Radioligand therapy offers a unique approach by combining a specific ligand targeting the HER2 protein with a radioisotope, thereby delivering radiation directly to cancer cells. This targeted therapy aims to damage the DNA of cancer cells, effectively shrinking tumors while minimizing harm to surrounding healthy tissue. Prospective patients undergo PET scans to confirm the presence of the HER2 protein in their tumors before participating in the trial.

Dr. Ramy Saleh, a medical oncologist at the Cedars Cancer Centre, emphasizes MUHC's emerging role as a leader in the field of radioligand therapy, noting the institution’s advanced infrastructure and commitment to innovation and precision medicine. The trial forms part of the broader efforts at MUHC to leverage cutting-edge research and advanced patient care in the rapidly evolving fields of theranostics and radioligand therapy.

A significant contributor to this initiative is the Centre for Innovative Medicine at the MUHC’s Glen site, a state-of-the-art facility providing specialized infrastructure to support complex clinical research. The success of this trial reflects the seamless collaboration between clinical, research, and nuclear medicine teams dedicated to advancing medical knowledge and offering new hope to patients through novel experimental therapies.

As the trial progresses, it holds promise for broadening treatment options and enhancing the quality of life for individuals with HER2-positive cancers that are resistant to current therapies.